Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
Create a narrative
Our community narratives are driven by numbers and valuation.
Create a narrative
Weekly Picks
Alphabet
BL
BlackGoat
Community Contributor
Alphabet: The Under-appreciated Compounder Hiding in Plain Sight
Summary Google trades at ~18× forward earnings — the cheapest among the Magnificent 7 Market is too focused on AI threats to Search and antitrust noise Meanwhile, Google is executing across AI, Cloud, and YouTube Key AI differentiator: unmatched distribution across 3B+ users via Search, Gmail, YouTube, Android, Chrome, and Cloud Quietly building a world-class AI infrastructure behind the scenes — including proprietary TPUs and a vertically integrated stack YouTube generated $8.93B in Q1 ad revenue (up 10% YoY); subscriptions hit 270M Google Cloud revenue up 28% YoY to $12.3B — now profitable Optionality from long-term bets like Waymo, DeepMind, and Verily Risk/reward is compelling — a strong candidate to beat the market long term Overview Despite being part of the "Magnificent Seven," Google’s stock lags due to perceived risks around disruption of its Search business from AI competitors and mounting antitrust concerns. But under the hood, Google has quietly built one of the most compelling setups in tech: with deep AI leadership, multiple high-growth businesses, and optionality from long-term moonshots like Waymo.
View narrative
US$268.43
FV
27.9% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
0
users have commented on this narrative
17
users have followed this narrative
21 days ago
author updated this narrative
Planet Labs PBC
AN
andreas_eliades
Community Contributor
Planet Labs: At The Heart Of The Emerging New Space Boom
Planet Labs leads the EO market with the largest satellite constellation, poised to capitalize on the growing demand for Earth Observation and geospatial data from companies and governments. Plunging space launch and GPU computation costs combined with advancements in CubeSat and AI technologies are boosting the utility of Earth Observation data.
View narrative
US$11.31
FV
43.8% undervalued
intrinsic discount
30.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
1
users have commented on this narrative
17
users have followed this narrative
New
narrative
Exxon Mobil
AG
Agricola
Community Contributor
Exxon in Guyana 5 year forecast Low $135 to High $189
Key Assumptions: Successful Guyana and South America Deposits: ExxonMobil’s Stabroek Block in Guyana is assumed to achieve full operational success, contributing significantly to production growth. The block is estimated to hold over 11 billion barrels of recoverable oil, with production scaling rapidly.
View narrative
US$189.00
FV
41.0% undervalued
intrinsic discount
14.85%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Community Investing Ideas
Load previous narratives
Super League Enterprise
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Diversified Portfolio And Mobile Games Will Drive Advertising Transformation
Key Takeaways Diversified revenue streams and strategic product advancements could enhance profit margins and accelerate the company's path to positive earnings. Expanding mobile gaming presence and transforming leadership could strengthen revenue opportunities and elevate the company's position in digital advertising.
View narrative
US$30.00
FV
83.2% undervalued
intrinsic discount
15.60%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
5 days ago
author updated this narrative
Actelis Networks
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Federal Certification And SaaS Offerings Will Unlock Smart City Prospects
Key Takeaways Increased federal and military orders, bolstered by key certifications, position Actelis Networks for continued growth impacting future revenue positively. Expansion of software services and strategic infrastructure projects increase revenue predictability and present substantial growth opportunities.
View narrative
US$5.00
FV
89.5% undervalued
intrinsic discount
36.58%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
5 days ago
author updated this narrative
Jaguar Health
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
FDA And EMA Fast-Track Approvals Will Advance Orphan Treatments
Key Takeaways New collaborations and regulatory approvals could quicken market entry, increase revenue, and improve earnings through enhanced access to global markets for orphan disease treatments. Expanding product indications and strategic launches aim to address unmet needs, potentially boosting revenue and elevating demand within targeted oncology markets.
View narrative
US$28.00
FV
92.0% undervalued
intrinsic discount
47.01%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
5 days ago
author updated this narrative
STRATA Skin Sciences
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Improved XTRAC Utilization And Expanded International Partnerships Will Secure Success
Key Takeaways Strategic removal of underperforming units and partnerships with clinics enhance device utilization and revenue potential. Growing international sales and TheraClearX adoption, coupled with insurance reimbursements, bolster future revenue prospects.
View narrative
US$9.00
FV
78.6% undervalued
intrinsic discount
5.27%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
5 days ago
author updated this narrative
Air Industries Group
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
New Aircraft Contracts And Facility Investments Will Expand Production Capacity
Key Takeaways Strong future revenue growth anticipated due to improved book-to-bill ratio and increased backlog. Investment in efficiency and military program alignment could boost margins and stabilize earnings amidst defense budget challenges.
View narrative
US$6.50
FV
46.3% undervalued
intrinsic discount
2.62%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
5 days ago
author updated this narrative
TeraGo
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Flexible Millimeter Wave Use Will Unlock Mobile Opportunities
Key Takeaways TERAGO's strategic mid-market focus and reduced churn anticipate future revenue growth, bolstered by improved account revenues and spectral assets. Enhanced operational and financial results, including EBITDA growth and increased cash flow, suggest stronger net margins and earnings potential.
View narrative
CA$2.00
FV
42.0% undervalued
intrinsic discount
4.46%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
5 days ago
author updated this narrative
Biovica International
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
DiviTum Entry Will Expand Breast Cancer Treatment Opportunities
Key Takeaways Biovica's strategic partnerships and agreements are expected to expand market penetration, potentially boosting sales and future revenue growth. New clinical trial data and collaborations may enhance adoption of DiviTum, improving revenue streams and profit margins.
View narrative
SEK 1.50
FV
55.3% undervalued
intrinsic discount
204.03%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
5 days ago
author updated this narrative
BioXcel Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
BXCL501 And SERENITY Trials Will Unlock New Treatment Horizons
Key Takeaways Advancing Phase III trials and successful SERENITY outcomes could expand market access and boost revenue through FDA approvals and new partnerships. Cost reduction initiatives and strategic financing strengthen financial stability, improving margins and enabling further commercialization efforts.
View narrative
US$23.25
FV
92.7% undervalued
intrinsic discount
224.44%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
12
users have followed this narrative
5 days ago
author updated this narrative
NextEd Group
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Expanding High-Demand Courses Will Strengthen Future Position
Key Takeaways Focus on higher-margin courses and efficient campus utilization is expected to boost revenue and stabilize margins. Expanding in-demand course offerings aligns with trends, potentially enhancing future revenue streams and market position.
View narrative
AU$0.33
FV
35.4% undervalued
intrinsic discount
3.46%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
5 days ago
author updated this narrative
Value any company in seconds
Popular companies